Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers February 23, 2017
Pharmacy Choice - News - U.S. Pharmaceutical Industry - February 23, 2017

Pharmacy News

 U.S. Pharmaceutical Industry
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

2/23/17 - 83% of Older Voters Want Medicare to Negotiate Drug Prices, Says Survey by the Senior Citizens League
Some 83 percent think Medicare should negotiate prescription drug prices for the Part D program. "The public thinks Medicare should negotiate drug prices just like the agency does for all other medical goods and services," says TSCL's Medicare and Social Security policy analyst, Mary Johnson. A complete repeal of the Affordable Care Act, known as
2/23/17 - Abeona Therapeutics Announces Dismissal of Securities Class Action Lawsuit
Abeona Therapeutics Inc., a leading clinical-stage biopharmaceutical company focused on developing therapies for life-threatening rare genetic diseases, announced today that on February 14, 2017, the plaintiff voluntarily dismissed the putative securities class action lawsuit he had recently filed against the company and certain members of its...
2/23/17 - Actinium Pharmaceuticals Announces Active Presence at the BMT Tandem Meetings
Actinium Pharmaceuticals, Inc., a biopharmaceutical company developing innovative targeted therapies for cancers lacking effective treatment options, announced today that the Company is attending the BMT Tandem Meetings, the combined annual meetings of the American Society of Blood and Marrow Transplantation and the Center for International Blood
2/23/17 - AmpliPhi Biosciences Establishes Scientific Advisory Board and Appoints Dr. Timothy Lu of MIT and Broad Institute as SAB Chairman
AmpliPhi Biosciences Corporation, a global leader in the development of bacteriophage-based therapies to treat drug-resistant bacterial infections, announces the formation of its Scientific Advisory Board and the appointment of Timothy K. Lu, M.D., Ph.D., as Chairman of the SAB. In 2017, AmpliPhi plans to initiate phage therapy studies in severa
2/23/17 - Analyst Downgrades ANI Pharmaceuticals (NASDAQ:ANIP) Stock Gets Downgraded By Roth Capital from Buy to Neutral
Analyst Ratings For ANI Pharmaceuticals (NASDAQ:ANIP) Today, ANI Pharmaceuticals (NASDAQ:ANIP) stock was downgraded by Roth Capital from Buy to Neutral with a price target of $69.00. There are 2 hold ratings, 3 buy ratings, 1 strong buy rating on the stock. The current consensus rating on ANI Pharmaceuticals (NASDAQ:ANIP) is Buy (Score: 2.83) with
2/23/17 - Ask The Doctors
DEAR DOCTOR: I had my thyroid removed because of papillary cancer, and my surgeon has advised me to take high levels of vitamin D. He says there may be a correlation between low vitamin D levels and the development of cancer and Alzheimer's disease. If I remember correctly, the normal blood range for vitamin D is between 30 and 60 nanograms per mil
2/23/17 - BeyondSpring Clinical Data for Lead Asset, Plinabulin, Accepted for Oral Presentation at IASLC's 2017 Targeted Therapies of the Treatment of Lung Cancer
BeyondSpring Pharmaceuticals, a clinical stage biopharmaceutical company focused on the development of innovative immuno-oncology cancer therapies, today announced that the Company's clinically and statistically significant data for its innovative lead asset, Plinabulin, has been accepted for oral presentation at this year's International...
2/23/17 - Biothera Pharmaceuticals Initiates Patient Dosing in Phase 2 Trial Investigating Imprime PGG and Merck's KEYTRUDA (pembrolizumab)
Biothera Pharmaceuticals, Inc. today announced that dosing has been initiated in a Phase 2 clinical trial evaluating Biothera s Imprime PGG in combination with the Merck anti-PD-1 therapy, KEYTRUDA , in patients with either advanced melanoma who have progressed on treatment with a checkpoint inhibitor therapy, or with TNBC whose disease has
2/23/17 - CBT Pharmaceuticals Presents Data Demonstrating Anti-Tumor Activity of its Programmed Death-1 antibody, CBT-501, at ASCO-SITC Clinical Oncology Symposium
The data were presented in a poster at the American Society of Clinical Oncology Society for Immunotherapy of Cancer Clinical Immuno-Oncology Symposium being held from February 23 25, 2017 in Orlando, Florida. The strong in-vivo preclinical data suggest that CBT-501 may have clinical benefit in a variety of tumor types, said Sanjeev Red
2/23/17 - Cellceutix Phase 2 Brilacidin Trial Progresses to Highest Dose Cohort for the Induction of Remission of Mild-to-Moderate Ulcerative Colitis [All Iraq News Agency (AIN)]
-Cellceutix Corporation,, a clinical stage biopharmaceutical company developing innovative therapies with dermatology, oncology, anti-inflammatory, and antibiotic applications, today announced progression of its ongoing Phase 2 clinical trial of Brilacidin to the third cohort for induction of remission of mild-to-moderate ulcerative colitis after..
2/23/17 - Chrysalis BioTherapeutics Initiates $5.45 Million Contract With NIH For Nuclear Countermeasure Development
By a News Reporter-Staff News Editor at Politics& Government Week- Chrysalis BioTherapeutics, Inc. announced initiation of a three-year $5.45 million contract with the National Institute of Allergy and Infectious Diseases to develop TP508 as a countermeasure to increase survival and reduce delayed effects of an accidental or intentional nuclear..
2/23/17 - Corbus Pharmaceuticals Announces Preclinical Data Demonstrating JBT-101 Reduces Inflammation in Alveolar Macrophages from Cystic Fibrosis Patients
Corbus Pharmaceuticals Holdings, Inc., a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that Michael Knowles, M.D., a member of the Company's Scientific Advisory Board and Professor of Pulmonary and Critical Care Medicine, University of North Carolina Chapel Hill will pre
2/23/17 - CTI BioPharma to Report Fourth Quarter and Full Year 2016 Financial Results on March 2, 2017
CTI BioPharma Corp. today announced that management plans to report its fourth quarter and full year 2016 financial results on Thursday, March 2, 2017, after the close of the U.S. financial markets. Thursday, March 2 1:30 p.m. PT/ 4:30 p.m. ET/ 10:30 p.m. CET 1-877-719-9788 +1 719-325-4802. CTI BioPharma Corp. is a biopharmaceutical company focus
2/23/17 - Curemark Announces Further Expansion of Clinical Sites For Its Phase 3 Clinical Trial for Children with Autism The Blm Study
Curemark, LLC announced today that the Blm Study, a Phase 3 clinical trial to evaluate the safety and efficacy of CM-AT in children aged 3-8 with Autism, is now enrolling at three new sites. Joan Fallon, founder and CEO of Curemark. "Making our clinical trial available to as many children across the United States as possible, is an important ste
2/23/17 - Cyclacel Announces Top-Line Results From Pivotal Phase 3 SEAMLESS Study in Elderly Patients With Acute Myeloid Leukemia
Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today reported top-line results from the pivotal Phase 3 SEAMLESS study in elderly patients aged 70 years or older with newly diagnosed acute myeloid le
2/23/17 - Diagnostic Imaging Market Worth 36.43 Billion by 2021
According to a new market research report " Diagnostic Imaging Market by Product, MRI, Ultrasound, CT, Nuclear Imaging), Application (OB/GYN, MSK, Cardiology, Oncology), End User (Hospitals, Imaging Centers)- Global Forecast to 2021", published by MarketsandMarkets, the report studies the global market over the forecast period of 2016 to 2021. The
2/23/17 - Earth Science Tech Initiates its Cannabis Cannabinoid-Based Composition of its 2 New Pharmaceutical Drugs and 3 Nutraceutical Patent Studies
Earth Science Tech, Inc., an innovative biotech company focused on hemp cannabinoid research and development, has begun composition work on its two new Cannabis Cannabinoid-Based pharmaceutical drugs and has initiated patent studies on its three new nutraceutical products. This is the first project Earth Science Tech and its wholly owned subsidia
2/23/17 - Executive-Level Specialty Medical and Biopharmaceutical Sales Management Professional Joins Cohera Medical, Inc. [Sudan Tribune]
-Cohera Medical, Inc., a leading innovator and developer of absorbable surgical adhesives and sealants, announced today the hiring of John Wyatt as Vice President of Sales. We are thrilled to welcome John to the Cohera team, said Patrick Daly, President and CEO of Cohera Medical, Inc. Johns experience in the aesthetic medical device and biopharmace
2/23/17 - Fibrocell Announces Dosing of First Patient in Phase I/II Clinical Trial of FCX-007 Gene Therapy for Treatment of Recessive Dystrophic Epidermolysis Bullosa
Fibrocell Science, Inc., a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today announced that the first patient has been dosed in the Phase I portion of the Phase I/II clinical trial of FCX-007, the Company s gene therapy candidate for the treatment of Recessive Dystro
2/23/17 - FinancialBuzz.com: Cannabis Market Creating Jobs
Earth Science Tech, Inc., Cannabis Sativa Inc., OWC Pharmaceutical Research Corporation, Canopy Growth Corporation, Mentor Capital Inc.. Just this morning Earth Science Tech, Inc. announced that it, "has begun composition work on its two new Cannabis Cannabinoid-Based pharmaceutical drugs and has initiated patent studies on its three new nutraceuti
2/23/17 - Flexion Therapeutics Initiates Clinical Trial to Evaluate the Safety of Repeat Administration of Zilretta? (FX006) in Patients with Osteoarthritis of the Knee
Flexion Therapeutics, Inc. today reported it has enrolled the first patient in a clinical trial to evaluate the safety of repeat administration of its investigational drug candidate Zilretta in patients with osteoarthritis of the knee. The open-label study is expected to enroll approximately 200 patients at up to 20 clinical sites in the United S
2/23/17 - Foamix Pharmaceuticals to Participate in a Panel Discussion at the Dermatology Innovation Forum
REHOVOT, Israel, and BRIDGEWATER, New Jersey, Feb. 23, 2017/ PRNewswire/ Foamix Pharmaceuticals Ltd.,, a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, announced today that Dr. Dov Tamarkin, CEO, will participate in a panel discussion entit
2/23/17 - Fusion Pharmaceuticals Launches with a $25M USD Series A Financing to Develop Targeted Radiotherapeutics as Cancer Treatments
Fusion Pharmaceuticals, a newly formed biopharmaceutical company developing targeted alpha-particle radiotherapeutics for treating cancer, today announced the closing of a $25 million Series A financing led by founding venture investor, Johnson& Johnson Innovation JJDC, Inc., with investments by HealthCap, TPG Biotech, Genesys Capital and FACIT.
2/23/17 - Global Antibody Drug Conjugates Market Outlook 2022: Market is Poised to Reach US$ 18.1 Billion [CPI Financial]
-Research and Markets has announced the addition of the "Global Antibody Drug Conjugates Market By Drug, Pipeline Analysis Outlook 2022" report to their offering. The ADC market is poised to reach US$ 18.1 Billion by 2022. In this report, there is in-depth market analysis of ADCETRIS and Kadcyla.
2/23/17 - Global Blood Therapeutics Prices a $125.0 Million Upsized Common Stock Public Offering [Gulf Daily News (Bahrain)]
A shelf registration statement relating to the shares of common stock offered in the public offering described above was filed with the Securities and Exchange Commission on October 14, 2016 and declared effective by the SEC on October 28, 2016. A preliminary prospectus supplement and accompanying prospectus relating to the offering have been filed
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415